Clinical Development Committee:
GSK:
[ * ]
Gilead:
[ * ]
Marketing Committee:
GSK:
[ * ]
Gilead:
[ * ]
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
G-1
QuickLinks
EXHIBIT 10.39
LICENSING AGREEMENT BY AND BETWEEN GILEAD WORLD MARKETS, LIMITED AND GLAXO GROUP
LIMITED
Table of Contents
EXHIBIT 10.39
LICENSING AGREEMENT
RECITALS
ARTICLE 1 DEFINITIONS
ARTICLE 2 MANAGEMENT
ARTICLE 3 DEVELOPMENT
ARTICLE 4 REGULATORY
ARTICLE 5 COMMERCIALIZATION
ARTICLE 6 DILIGENCE
ARTICLE 7 LICENSES
ARTICLE 8 MANUFACTURE AND SUPPLY
ARTICLE 9 COMPENSATION
ARTICLE 10 INTELLECTUAL PROPERTY
ARTICLE 11 REPRESENTATIONS AND WARRANTIES
ARTICLE 12 INDEMNIFICATION
ARTICLE 13 RECORDS; AUDITS; PUBLICATIONS
ARTICLE 14 CONFIDENTIALITY
ARTICLE 15 TERM AND TERMINATION
ARTICLE 16 DISPUTE RESOLUTION
ARTICLE 17 MISCELLANEOUS
EXHIBIT A CURRENT GILEAD TRIALS
EXHIBIT B GILEAD NAMES AND LOGO; POTENTIAL GILEAD PRODUCT MARK
EXHIBIT C COUNTRIES OF THE GILEAD TERRITORY
EXHIBIT D OTHER CLINICAL TRIAL AGREEMENTS
EXHIBIT E SAFETY DATA EXCHANGE PROTOCOL Safety monitoring of adefovir dipivoxil
between Global Clinical Safety & Pharmacovigilance, GlaxoSmithKline And Global
Drug Safety, Gilead Sciences
EXHIBIT F PRESS RELEASE
GILEAD AND GLAXOSMITHKLINE ANNOUNCE INTERNATIONAL LICENSING AGREEMENT FOR
INVESTIGATIONAL CHRONIC HEPATITIS B DRUG ADEFOVIR DIPIVOXIL
.......... GLAXOSMITHKLINE AND GILEAD ANNOUNCE INTERNATIONAL LICENSING AGREEMENT
TO COMMERCIALISE ADEFOVIR DIPIVOXIL FOR THE TREATMENT OF CHRONIC HEPATITIS B
# # #
EXHIBIT G COMMITTEE MEMBERS